Cynata Therapeutics: Receives approval for acute graft-versus-host disease clinical trial

January 30, 2023

518

Must read

Diligent Technical Lead with 9 years of experience in software development. Successfully lead project management teams to build technological products. Exposed to software development life cycle including requirement analysis, program design, development and unit testing and application maintenance. Has worked on Java, PHP, PL/SQL, Oracle forms and Reports, Oracle, Bootstrap, structs, jQuery, Ajax, java script, CSS, Microsoft Excel, Microsoft Word, C++, and Microsoft Office.

Cynata Therapeutics Receives approval for acute graft-versus-host disease clinical trial

Cynata Therapeutics (CYP) receives approval to launch a phase two clinical trial in acute graft-versus-host disease
The clinical stage biotech company was granted the green light to undertake the trial from Advarra, a central institutional research board (IRB) service provider in the US
IRB approval is considered an “essential step” in the process of opening clinical study sites and starting trials in humans in America
Cynata expects the trial will be conducted in around 60 patients at sites across the US, Europe, and Australia
CynataTherapeutics last traded at 31 cents at 2:47 pm AEDT